Q32 Bio (QTTB) stock price is $8.62, up 10.65% on the day, as of Oct 20, 2026. It has a market cap of $175.15Mn and a P/E ratio of 43.84, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap175.15 Mn
P/E43.84
P/S137.69
Div. Yield0.00
Revenue Growth (1y) (Qtr)13.38
Add ratio to table…
About
Q32 Bio Inc. is a clinical stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company’s lead product candidate, bempikibart (ADX-914), is a fully human anti‑interleukin‑7 receptor alpha antagonist monoclonal antibody designed to block signaling mediated by interleukin‑7 and thymic stromal…
Q32 Bio Inc. is a clinical stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company’s lead product candidate, bempikibart (ADX-914), is a fully human anti‑interleukin‑7 receptor alpha antagonist monoclonal antibody designed to block signaling mediated by interleukin‑7 and thymic stromal lymphopoietin. In addition to bempikibart, Q32 Bio maintains a preclinical tissue‑targeted complement inhibitor platform that includes assets such as ADX-096. The company also explores the therapeutic potential of its tissue‑targeted complement inhibitor platform for indications such as geographic atrophy and other complement‑mediated diseases. Q32 Bio’s strategy is to advance bempikibart through clinical trials while evaluating strategic options for its complement pipeline assets.
Q32 Bio generates revenue primarily through licensing and collaboration agreements that provide upfront payments, development and regulatory milestones, commercial milestones, and tiered royalties on net sales of licensed products. For example, the company received an $8 million upfront payment from Bristol‑Myers Squibb under a license agreement for bempikibart and is eligible for additional milestone payments and royalties. Under the BMS license agreement, Q32 Bio is eligible to receive up to $49 million in development and regulatory milestones per indication and up to $215 million in commercial milestones, along with tiered royalties ranging from mid single digit percentages to 10 percent of net sales. In November 2025, Q32 Bio sold its ADX-097 asset to Akebia Therapeutics, receiving a $7 million upfront payment, a $3 million payment six months after closing, and potential milestones worth up to $580 million plus tiered royalties. The ADX-097 sale also includes a potential near term milestone of $2 million payable upon achievement of the first milestone or by December 31, 2026. These arrangements constitute the company’s current sources of income while it advances its product candidates through clinical development.
Within the biotechnology sector focused on autoimmune and inflammatory diseases, Q32 Bio competes with established therapies such as Janus kinase inhibitors (e.g., baricitinib and ritlecitinib) that are currently approved for severe alopecia areata, as well as other biologic agents targeting interleukins or complement pathways. The company’s competitive advantage lies in its dual inhibition of interleukin‑7 and thymic stromal lymphopoietin signaling through bempikibart, a mechanism that addresses both adaptive and epithelial immune pathways and has demonstrated a favorable safety profile with no grade 3 or higher treatment related adverse events in clinical trials. Few competitors currently target the interleukin‑7 pathway, giving Q32 Bio a differentiated position in the alopecia areata landscape. The company’s intellectual property estate includes issued patents covering bempikibart composition expected to expire in 2040 and methods of use protected until 2044, providing a long runway for exclusivity. Additionally, the FDA’s grant of Fast Track designation for bempikibart in alopecia areata underscores the perceived unmet medical need and may expedite development and review.
Q32 Bio’s current customers are primarily pharmaceutical and biotechnology partners with whom it collaborates on drug development and licensing. Notable collaborators include Bristol‑Myers Squibb, which holds a license to bempikibart, and Akebia Therapeutics, which acquired the ADX-097 asset. Looking forward, the company intends to serve patients suffering from alopecia areata, atopic dermatitis, and other immune mediated conditions once its therapies receive regulatory approval. In the future, the company anticipates that its therapies will be prescribed by dermatologists and reimbursed by government programs such as Medicare and Medicaid as well as private health insurers. These stakeholders represent the target customer base for Q32 Bio’s eventual commercial products.
Sector:HealthcareSector rationaleQ32 Bio is a clinical-stage biotechnology company that develops biologics and monoclonal antibodies, such as bempikibart, to treat autoimmune and inflammatory diseases. Its revenue model is based on licensing and collaboration agreements with pharmaceutical partners like Bristol-Myers Squibb and Akebia Therapeutics for the development of medical therapies.Industry:BiotechnologyBiotechnologyPrimaryQ32 Bio is a clinical-stage biotechnology company developing biologics, specifically monoclonal antibodies like bempikibart (ADX-914) and a tissue-targeted complement inhibitor platform. Its revenue is derived from collaboration and licensing agreements with partners such as Bristol-Myers Squibb and Akebia Therapeutics, which include upfront payments and milestones.Classified using BQ-MICSCIK: 0001661998
Bull & bear
Investment Thesis
▲ Bull case
Q32 Bio has successfully secured significant non-dilutive financing through strategic asset monetization and private placements, positioning the company to advance its lead asset bempikibart without immediate financing pressure. The May 2026 $55 million private placement, led by top-tier institutional investors including BVF Partners, RA Capital, OrbiMed, and Atlas Venture, combined with the $10.5 million registered direct offering and guaranteed milestone payments from the ADX-097 asset sale to Akebia Therapeutics, provides substantial financial flexibility. This capital structure allows Q32 Bio to fully fund the SIGNAL-AA Phase 2b trial readout expected in mid-2026 and potentially initiate pivotal trials without seeking additional dilutive financing in the near term. The participation of blue-chip healthcare-focused investors signals strong conviction in bempikibart’s mechanism of action targeting the IL-7Rα pathway, which has genetic and biological validation across multiple autoimmune indications beyond alopecia areata. This investor base not only provides capital but also potential strategic partnerships and validation that could accelerate development timelines and enhance credibility with regulators and future collaborators. The company’s ability to attract such sophisticated investors despite being clinical-stage with no approved products underscores confidence in its scientific approach and de-risked development path for bempikibart.
The SIGNAL-AA Phase 2a trial (Part B) is progressing ahead of expectations with completed enrollment of 33 patients—exceeding the original target—and early signs of clinical activity combined with favorable pharmacokinetic data supporting continued dosing in the open-label extension (OLE). The fact that patients are electing to continue treatment in the OLE portion after completing the double-blind phase is a strong real-world signal of perceived benefit and tolerability, which is particularly meaningful in alopecia areata where treatment burden and relapse rates are high with current options. This patient-driven demand for extended access suggests bempikibart may offer a favorable risk-benefit profile compared to existing therapies like JAK inhibitors, which carry safety concerns including thrombosis, malignancy risk, and lipid abnormalities. The IL-7Rα mechanism targets upstream immune regulation, potentially offering a more durable rebalancing of immunity rather than broad immunosuppression, which could translate to longer remission periods and better long-term safety—key unmet needs in the AA patient population. Mid-2026 topline data from Part B could therefore serve as a major inflection point, potentially showing statistically significant improvement in SALT scores or durable response rates that would justify rapid advancement to pivotal trials.
The strategic divestiture of the non-core ADX-097 asset to Akebia Therapeutics has not only provided immediate cash but also structured near-term milestone payments that extend the company’s financial runway into 1H 2028, as explicitly stated in multiple filings. This move sharpens Q32 Bio’s focus on bempikibart for alopecia areata, eliminating distraction from parallel programs and allowing full allocation of scientific, clinical, and financial resources toward its lead asset. The ADX-097 sale generated an upfront payment of approximately $11.7 million (as seen in Q4 2025 financials) with additional milestones tied to development, regulatory, and commercial success—creating a potential future revenue stream without requiring further investment. This clean strategic pivot reduces optionality risk and aligns the entire organization around a single near-term value driver: proving bempikibart’s efficacy in AA. With cash equivalents of $50.8 million as of March 31, 2026, plus the recent $55 million placement and expected ATM proceeds, the company is well-capitalized to execute through multiple value inflection points, including potential Phase 2b initiation and even early preparatory work for a Phase 3 program, should mid-2026 data be positive.
Q32 Bio has successfully secured significant non-dilutive financing through strategic asset monetization and private placements, positioning the company to advance its lead asset bempikibart without immediate financing pressure. The May 2026 $55 million private placement, led by top-tier institutional investors including BVF Partners, RA Capital, OrbiMed, and Atlas Venture, combined with the $10.5 million registered direct offering and guaranteed milestone payments from the ADX-097 asset sale to Akebia Therapeutics, provides substantial financial flexibility. This capital structure allows Q32 Bio to fully fund the SIGNAL-AA Phase 2b trial readout expected in mid-2026 and potentially initiate pivotal trials without seeking additional dilutive financing in the near term. The participation of blue-chip healthcare-focused investors signals strong conviction in bempikibart’s mechanism of action targeting the IL-7Rα pathway, which has genetic and biological validation across multiple autoimmune indications beyond alopecia areata. This investor base not only provides capital but also potential strategic partnerships and validation that could accelerate development timelines and enhance credibility with regulators and future collaborators. The company’s ability to attract such sophisticated investors despite being clinical-stage with no approved products underscores confidence in its scientific approach and de-risked development path for bempikibart.
The SIGNAL-AA Phase 2a trial (Part B) is progressing ahead of expectations with completed enrollment of 33 patients—exceeding the original target—and early signs of clinical activity combined with favorable pharmacokinetic data supporting continued dosing in the open-label extension (OLE). The fact that patients are electing to continue treatment in the OLE portion after completing the double-blind phase is a strong real-world signal of perceived benefit and tolerability, which is particularly meaningful in alopecia areata where treatment burden and relapse rates are high with current options. This patient-driven demand for extended access suggests bempikibart may offer a favorable risk-benefit profile compared to existing therapies like JAK inhibitors, which carry safety concerns including thrombosis, malignancy risk, and lipid abnormalities. The IL-7Rα mechanism targets upstream immune regulation, potentially offering a more durable rebalancing of immunity rather than broad immunosuppression, which could translate to longer remission periods and better long-term safety—key unmet needs in the AA patient population. Mid-2026 topline data from Part B could therefore serve as a major inflection point, potentially showing statistically significant improvement in SALT scores or durable response rates that would justify rapid advancement to pivotal trials.
The strategic divestiture of the non-core ADX-097 asset to Akebia Therapeutics has not only provided immediate cash but also structured near-term milestone payments that extend the company’s financial runway into 1H 2028, as explicitly stated in multiple filings. This move sharpens Q32 Bio’s focus on bempikibart for alopecia areata, eliminating distraction from parallel programs and allowing full allocation of scientific, clinical, and financial resources toward its lead asset. The ADX-097 sale generated an upfront payment of approximately $11.7 million (as seen in Q4 2025 financials) with additional milestones tied to development, regulatory, and commercial success—creating a potential future revenue stream without requiring further investment. This clean strategic pivot reduces optionality risk and aligns the entire organization around a single near-term value driver: proving bempikibart’s efficacy in AA. With cash equivalents of $50.8 million as of March 31, 2026, plus the recent $55 million placement and expected ATM proceeds, the company is well-capitalized to execute through multiple value inflection points, including potential Phase 2b initiation and even early preparatory work for a Phase 3 program, should mid-2026 data be positive.
Despite the optimistic financing narrative, Q32 Bio remains a pre-revenue clinical-stage company with no approved products and a history of relying heavily on dilutive financing to sustain operations, raising concerns about long-term shareholder value creation even if bempikibart succeeds. The company has consistently operated at a significant net loss, with Q1 2026 reporting a $7.6 million loss and full-year 2025 showing a $29.8 million net income only due to the one-time gain on the ADX-097 asset sale—stripping that out, the underlying business continues to burn cash at an alarming rate. The recent $55 million private placement, while seemingly strong, was conducted at $8.00 per share, representing a substantial premium over the February 2026 registered direct offering price of $3.90, suggesting the earlier financing was a distressed raise and the current one may reflect opportunistic pricing by sophisticated investors who perceive near-term catalysts as already priced in or overestimated. This pattern of frequent capital raises—including the $10.5 million RDO, $14.2 million in ATM proceeds, and now $55 million in a private placement—indicates persistent financing dependence and heightens the risk of cumulative dilution, especially if clinical milestones are delayed or fail to meet expectations, forcing further down-round financing that could severely erode existing shareholders’ stakes.
The SIGNAL-AA Phase 2a trial, while fully enrolled, remains an early-stage study with no placebo-controlled data yet released, and the company’s reliance on pharmacokinetic signals and patient interest in the OLE as proxies for efficacy introduces significant interpretive risk. There is no guarantee that the observed clinical activity to date will translate into statistically significant or clinically meaningful endpoints at 36 weeks, particularly given the high placebo response rates historically seen in alopecia areata trials and the variability in disease measurement (e.g., SALT scores). The IL-7Rα mechanism, while biologically plausible, has not yet been validated in a pivotal trialsetting for any indication, and bempikibart’s ability to durably modulate immune function without causing broad immunosuppression or adverse events remains unproven at scale. Furthermore, the alopecia areata landscape is rapidly evolving, with multiple JAK inhibitors (e.g., baricitinib, ritlecitinib) either approved or in late-stage development, creating a high bar for differentiation—especially if bempikibart shows only modest efficacy or requires frequent dosing, which could limit its commercial viability despite a favorable safety profile.
Q32 Bio’s financial runway projections are highly dependent on the successful achievement of multiple contingent milestones, including timely completion of the SIGNAL-AA Part B readout by mid-2026, receipt of guaranteed payments from the ADX-097 sale, and continued access to ATM financing—all of which carry execution and market risk. The assertion that cash will last into 1H 2028 assumes no setbacks in clinical trials, no unexpected manufacturing or regulatory delays, and continued investor appetite for biotech financings in a potentially volatile macro environment. If the mid-2026 data readout is negative or inconclusive, the company would likely need to raise additional capital immediately under unfavorable conditions, potentially triggering a downward spiral of dilution and declining investor confidence. Moreover, the reliance on milestone payments from Akebia for ADX-097 introduces counterparty risk—should Akebia fail to advance the asset due to its own clinical or strategic shifts, those payments may never materialize, undermining the projected financial cushion. This creates a scenario where the company’s optimism is predicated on a chain of uncertain events, any break in which could rapidly deplete resources and force a strategic retreat or fire-sale partnership on unfavorable terms.
Despite the optimistic financing narrative, Q32 Bio remains a pre-revenue clinical-stage company with no approved products and a history of relying heavily on dilutive financing to sustain operations, raising concerns about long-term shareholder value creation even if bempikibart succeeds. The company has consistently operated at a significant net loss, with Q1 2026 reporting a $7.6 million loss and full-year 2025 showing a $29.8 million net income only due to the one-time gain on the ADX-097 asset sale—stripping that out, the underlying business continues to burn cash at an alarming rate. The recent $55 million private placement, while seemingly strong, was conducted at $8.00 per share, representing a substantial premium over the February 2026 registered direct offering price of $3.90, suggesting the earlier financing was a distressed raise and the current one may reflect opportunistic pricing by sophisticated investors who perceive near-term catalysts as already priced in or overestimated. This pattern of frequent capital raises—including the $10.5 million RDO, $14.2 million in ATM proceeds, and now $55 million in a private placement—indicates persistent financing dependence and heightens the risk of cumulative dilution, especially if clinical milestones are delayed or fail to meet expectations, forcing further down-round financing that could severely erode existing shareholders’ stakes.
The SIGNAL-AA Phase 2a trial, while fully enrolled, remains an early-stage study with no placebo-controlled data yet released, and the company’s reliance on pharmacokinetic signals and patient interest in the OLE as proxies for efficacy introduces significant interpretive risk. There is no guarantee that the observed clinical activity to date will translate into statistically significant or clinically meaningful endpoints at 36 weeks, particularly given the high placebo response rates historically seen in alopecia areata trials and the variability in disease measurement (e.g., SALT scores). The IL-7Rα mechanism, while biologically plausible, has not yet been validated in a pivotal trialsetting for any indication, and bempikibart’s ability to durably modulate immune function without causing broad immunosuppression or adverse events remains unproven at scale. Furthermore, the alopecia areata landscape is rapidly evolving, with multiple JAK inhibitors (e.g., baricitinib, ritlecitinib) either approved or in late-stage development, creating a high bar for differentiation—especially if bempikibart shows only modest efficacy or requires frequent dosing, which could limit its commercial viability despite a favorable safety profile.
Q32 Bio’s financial runway projections are highly dependent on the successful achievement of multiple contingent milestones, including timely completion of the SIGNAL-AA Part B readout by mid-2026, receipt of guaranteed payments from the ADX-097 sale, and continued access to ATM financing—all of which carry execution and market risk. The assertion that cash will last into 1H 2028 assumes no setbacks in clinical trials, no unexpected manufacturing or regulatory delays, and continued investor appetite for biotech financings in a potentially volatile macro environment. If the mid-2026 data readout is negative or inconclusive, the company would likely need to raise additional capital immediately under unfavorable conditions, potentially triggering a downward spiral of dilution and declining investor confidence. Moreover, the reliance on milestone payments from Akebia for ADX-097 introduces counterparty risk—should Akebia fail to advance the asset due to its own clinical or strategic shifts, those payments may never materialize, undermining the projected financial cushion. This creates a scenario where the company’s optimism is predicated on a chain of uncertain events, any break in which could rapidly deplete resources and force a strategic retreat or fire-sale partnership on unfavorable terms.